InsightRX Advisory Board

Dr. Boyle’s research uses advanced techniques in quantitative pharmacology and clinical trial design to improve the use of narrow therapeutic drugs in pediatric patients requiring chemotherapy and immunosuppression for the treatment of cancer, hematopoietic cell transplantation and gene therapy.  Dr Boyle aims to optimize complex drug therapy in children undergoing treatment for life-threatening disease, in part by reducing the technical barriers of implementation and adoption of population pharmacokinetic models into routine clinical practice.

Dr. Savic’s research uses computational methods to study the dynamic interplay between disease progression, drug and biomarker response across relevant scales (molecule, cell, tissue, organ & whole body) in order to determine causal links underlying variability in (safety and efficacy) clinical outcomes. Her goal is to determine the optimal dosage, timing, and duration of therapeutic regimens and ultimately develop precise, personalized treatments.

Dr. Peck has over 30 years’ experience as a clinical pharmacologist with Glaxo Wellcome, Eli Lilly and Roche. His group at Hoffmann-La Roche defines dosing and explores response variability for small and large molecules throughout development, regulatory approval and subsequent clinical use. His current research focus is to develop ways to identify precision dosing algorithms in early clinical development that could be tested in pivotal pre-approval clinical trials, thereby enabling precision dosing to be integral to approval for new drugs. He earned his medical degree at St. John’s College, Cambridge University and worked for several years as a hospital physician before embarking on a career in clinical pharmacology.

Dr. Rybak is an experienced Professor of Pharmacy and Medicine with an extensive history of working in higher education with a focus in antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious disease health outcomes, including their relationship to bacterial resistance. 

Dr. Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing and informatics technologies to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels.

Dr. Neely is the the director of the University of Southern California Laboratory of Applied Pharmacokinetics and Bioinformatics, and a Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at the Children’s Hospital of Los Angeles (CHLA). Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and the use models to optimize therapy for individual patients.

Grace has more than 25 years of experience in the medical device industry and has spent over 15 years working directly in medical device startups, helping to bring companies from initial funding to full operations. Grace has led a team of quality, regulatory and clinical personnel in providing consulting services for a wide variety of projects including: preparation of 510(k), PMA, CE and Canadian applications; Design History File and Device Master Record preparation; preparation and execution of multi-site clinical studies; establishment and improvement of Quality Systems; conduct of formal Quality System audits and leading FDA/NB inspections; development and execution of device verifications and validations, and software tool validation to comply with 21 CFR 11 and process validation requirements.

Ashfaq is a Senior Technology Executive with broad and deep technical and business knowledge along with proven ability to motivate teams and deliver results at scale. He is a deeply strategic thinker able to quickly synthesize data and transform it into market opportunity and competitive advantage. Ashfaq is also an ML7 fellow at the University of Toronto’s Joseph L. Rotman School of Management.